This site is intended for healthcare professionals

Go to /pro/cpd-dashboard page

This podcast episode is worth 0.23 CPD credits. CPD Dashboard

Go to /account/subscription-details page

This podcast episode is worth 0.23 CPD credits. Upgrade to Pro

Ep 18 – Managing the risk of drug-induced QT prolongation in primary care

00:00
00:00

Posted 8 Oct 2020

Dr Kevin Fernando

In the first episode in a new season of the podcast, Kevin discusses helpful guidance on the corrected QT interval in the context of primary care prescribing. Why should we be concerned about prolongation of the QT interval? Which medications can affect QT interval? What other risk factors for QT prolongation should be considered? And for which patients should we recommend electrocardiogram monitoring?

 

Key references and resources discussed in the episode:


Key take-home points from the episode include:

  1. The risk of a prolonged QTc interval and torsades de pointes depends on patient clinical factors such as electrolyte disturbance or a history of cardiovascular disease, as well as medication history.
  2. CredibleMeds is a useful website categorising drugs by their potential to prolong the QTc interval.
  3. Electrocardiogram monitoring should be considered on an individual basis for those at highest risk.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.